The Charcot-Marie-Tooth Association announced a $110,500 investment partnering with La Jolla Labs to develop an antisense oligonucleotide medicine targeting CMT2A, the most common axonal form of CMT, using a novel approach to increase MFN1 expression.
CMTA Invests $165,000 in CMT1A and CMT1E Treatments
CMTA invests $165,000 in University of Iowa research led by Michael Shy, MD, and Robert Piper, PhD, to determine the right time to begin treatment for CMT1A and CMT1E.
CMTA Adds $225,720 for CMT1B and CMT1E Drug Repurposing
CMTA is investing $225,720 to expand drug repurposing research into CMT1B and CMT1E, building on ongoing CMT1A research targeting shared disease mechanisms.
CMTA Appoints Aimee Yrlas Simpson as Chief Revenue Officer
CMTA appoints Aimee Yrlas Simpson as Chief Revenue Officer, bringing more than 25 years of nonprofit leadership experience to help advance research and support people living with CMT.
Vincent Timmerman Joins CMTA-STAR Scientific Advisory Board
Vincent Timmerman, PhD, the Belgian geneticist whose lab identified the first known genetic cause of Charcot-Marie-Tooth disease, joins the CMTA-STAR Scientific Advisory Board. Timmerman brings three decades of CMT genetics research and iPSC disease modeling expertise to CMTA's push to advance therapies into clinical trials.
CMTA Receives $154,000 ACA Grant for Camp Footprint
CMTA has received a $154,000 American Camp Association Character at Camp Implementation Grant to launch the Footprint Fellowship: Bringing Camp Magic Home. The two-year initiative extends the Camp Footprint experience beyond summer for 35 inaugural Fellows and positions the program as a national model for character-driven camp programming.
CMTA Invests $141,000 to Study Hearing and Balance in CMT
CMTA is supporting a two-year research project examining hearing and balance signaling to strengthen outcome measures in future CMT clinical trials.
CMTA Adds David Stark and Catherine Illingworth to Board
CMTA welcomes David Stark, MD, and Catherine Illingworth to its Board of Directors, strengthening clinical insight and gene therapy leadership within the CMT community.
CMTA Tackles CMT Delivery Challenge With Four Investments
CMTA announced $523,000 in funding for four research projects focused on solving one of the biggest challenges in CMT treatment development: delivering therapies to peripheral nerve cells. By investing in genome-editing transport, blood-nerve barrier crossing, Schwann cell targeting, and nanoparticle systems, CMTA is working to ensure treatments can reach the cells where they are needed.
CMTA Appoints Wendy Arnone as Board Chair
CMTA has appointed Wendy Arnone as board chair, succeeding Gilles Bouchard, who has led the board since 2016 and will continue serving as a board member. Arnone brings decades of executive healthcare leadership experience and a clinical background as a registered nurse, positioning her to guide CMTA’s continued investment in research and drug development for CMT.
